Ascentage Pharma Group International (NASDAQ:AAPG) Hits New 52-Week Low – Time to Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $17.10 and last traded at $17.57, with a volume of 5393 shares changing hands. The stock had previously closed at $18.28.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AAPG. China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 target price on the stock. Finally, BTIG Research reissued a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. Based on data from MarketBeat.com, Ascentage Pharma Group International currently has a consensus rating of “Buy” and an average target price of $46.67.

Ascentage Pharma Group International Price Performance

The business’s 50-day simple moving average is $22.73 and its two-hundred day simple moving average is $25.26. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $24.72 million for the quarter. On average, sell-side analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current year.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently modified their holdings of AAPG. XY Capital Ltd boosted its holdings in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares in the last quarter. UBS Group AG lifted its holdings in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International in the 2nd quarter worth $391,000. Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth $383,000. Finally, ABC Arbitrage SA bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.